Click on the company for more information on the subsidy award. Click on the parent name to reach the summary page for that parent company.
Company | Parent | Location | Subsidy Source | Year | Subsidy Value | Loan/Bailout Value | Type of Subsidy |
---|---|---|---|---|---|---|---|
Lannett Company, Inc. | Lannett Co. | Pennsylvania | state | $500,000 | grant | ||
Johnson & Johnson Sales and Logistics Company, LLC | Johnson & Johnson | Pennsylvania | state | $500,000 | grant | ||
Barr Laboratories Inc. | Teva Pharmaceutical Industries | Virginia | state | 2008 | $500,000 | grant | |
MedImmune, Inc. | AstraZeneca | Maryland | local | $500,000 | grant/loan hybrid program | ||
Eli Lilly dba Elanco Animal Health | Eli Lilly | Indiana | state | 2013 | $500,000 | grant | |
Wyeth-Lederle (#2) | Pfizer | North Carolina | state | 2004 | $500,000 | grant | |
Novitas Solutions, Inc. | Novartis | Florida | state | 2013 | $500,000 | tax credit/rebate | |
Anda Pharmaceuticals, Inc. | AbbVie | Mississippi | state | 2012 | $500,000 | grant | |
C3i, Inc. | Merck | Pennsylvania | state | $500,000 | grant | ||
Pfizer, Inc. | Pfizer | New York | state | 2005 | $500,000 | enterprise zone | |
United Therapeutics | United Therapeutics | Maryland | local | 2018 | $500,000 | grant/loan hybrid program | |
Supernus Pharmaceuticals | Supernus Pharmaceuticals | Maryland | local | 2018 | $500,000 | grant/loan hybrid program | |
Supernus Pharmaceuticals | Supernus Pharmaceuticals | Maryland | local | 2018 | $500,000 | grant/loan hybrid program | |
Intervet, Inc. D/B/A Merck | Merck | Nebraska | state | 2019 | $500,000 | grant | |
Supernus Pharmaceuticals | Supernus Pharmaceuticals | Maryland | local | 2019 | $500,000 | grant/loan hybrid program | |
Merck | Merck | Virginia | state | 2007 | $500,000 | grant | |
Idexx Laboratories, Inc. | IDEXX Laboratories | Maine | state | 2020 | $497,199 | tax credit/rebate | |
Pfizer, Inc. | Pfizer | North Carolina | state | 2018 | $495,412 | tax credit/rebate | |
American Pharmaceutical Partners, Inc. | Bristol-Myers Squibb | New York | local | 2005 | $495,039 | tax credit/rebate; property tax abatement | |
Emergent Biosolutions | Emergent BioSolutions | Maryland | local | 2013 | $495,000 | grant | |
Acorda Therapeutics, Inc. | Acorda Therapeutics | Massachusetts | state | 2017 | $495,000 | tax credit/rebate | |
GLAXOSMITHKLINE & Stiefel Laboratories Inc. | GlaxoSmithKline | New York | Local | 2018 | $494,593 | tax credit/rebate | |
Cambrex Charles City, Inc. | Cambrex | Iowa | state | 2020 | $494,275 | grant/loan hybrid program | |
Medimmune, LLC | AstraZeneca | Maryland | state | 2009 | $490,223 | tax credit/rebate | |
Merrimack Pharmaceuticals, Inc | Merrimack Pharmaceuticals | Massachusetts | state | 2013 | $490,000 | tax credit/rebate | |
GLAXOSMITHKLINE & Stiefel Laboratories Inc. | GlaxoSmithKline | New York | local | 2011 | $488,081 | tax credit/rebate; property tax abatement | |
IMMUNEX CORPORATION | Amgen | Washington | state | 2006 | $485,991 | tax credit/rebate | |
Abbott Laboratories | Abbott Laboratories | Illinois | state | 2008 | $485,631 | tax credit/rebate | |
Hospira, Inc. | Pfizer | North Carolina | state | 2013 | $483,750 | grant | |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2004 | $481,822 | tax credit/rebate | |
Forest Research Institute, Inc. | AbbVie | Pennsylvania | state | 2011 | $481,489 | tax credit/rebate | |
Bristol Myers Squibb (Mr. Leon Squibb) | Bristol-Myers Squibb | New York | local | 2007 | $478,724 | tax credit/rebate; property tax abatement | |
Novozymes Blair, Inc. | Novo Holdings A/S | Nebraska | state | 2023 | $475,775 | tax rebate | |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2008 | $474,786 | tax credit/rebate | |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New Jersey | state | 2008 | $471,219 | grant | |
GLAXOSMITHKLINE & Stiefel Laboratories Inc. | GlaxoSmithKline | New York | local | 2013 | $470,487 | tax credit/rebate; property tax abatement | |
Biogen Idec MA, Inc. | Biogen | North Carolina | state | 2017 | $467,431 | tax credit/rebate | |
Novartis Animal Health US, Inc. | Novartis | Iowa | state | 2007 | $466,425 | tax credit/rebate | |
Auxilium Pharmacueticals, Inc. | Endo International | Pennsylvania | state | 2013 | $465,755 | tax credit/rebate | |
GLAXOSMITHKLINE & Stiefel Laboratories Inc. | GlaxoSmithKline | New York | local | 2012 | $464,160 | tax credit/rebate; property tax abatement | |
Doral/Pfizer | Pfizer | New York | local | 2008 | $462,392 | tax credit/rebate; property tax abatement | |
Medimmune, LLC | AstraZeneca | Maryland | state | 2011 | $462,285 | tax credit/rebate | |
Endo Pharmaceuticals | Endo International | Pennsylvania | state | $462,000 | tax credit/rebate | ||
Abiomed, Inc | Johnson & Johnson | Massachusetts | state | 2019 | $459,125 | tax credit/rebate | |
Cambrex Charles City, Inc. | Cambrex | Iowa | state | 2020 | $458,408 | training reimbursement | |
C3i Incorporated | Merck | Pennsylvania | state | $458,000 | tax credit/rebate | ||
Idexx Laboratories, Inc. | IDEXX Laboratories | Maine | state | 2017 | $456,553 | tax credit/rebate | |
Ventana Medical Systems, Inc. | Roche | Arizona | state | 2007 | $454,796 | training reimbursement | |
Endo Pharmaceuticals, Inc. | Endo International | Pennsylvania | state | 2012 | $454,512 | tax credit/rebate | |
Hi-Tech Pharmacal, Inc. | Akorn Inc. | New York | state | 2009 | $453,858 | enterprise zone | |
Hi-Tech Pharmacal, Inc. | Akorn Inc. | New York | state | 2009 | $453,858 | enterprise zone | |
Hi-Tech Pharmacal, Inc. | Akorn Inc. | New York | state | 2009 | $453,858 | enterprise zone | |
Viropharma Incorporated | Takeda Pharmaceutical | Pennsylvania | state | $453,000 | tax credit/rebate | ||
Merck & Co., Inc. | Merck | North Carolina | state | 2008 | $452,785 | tax credit/rebate | |
Novartis Pharmaceuticals Corp. & Affiliates | Novartis | Nebraska | state | 2007 | $452,433 | tax credit/rebate | |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2014 | $452,064 | tax credit/rebate | |
Mylan Inc. | Viatris | Pennsylvania | state | $450,000 | tax credit/rebate | ||
Moderna Therapeutics | Moderna Inc. | Massachusetts | state | 2014 | $450,000 | tax credit/rebate | |
Sucampo Pharmaceuticals, Inc. | Mallinckrodt | Maryland | state | 2016 | $450,000 | grant/loan hybrid program | |
Merck (2015) | Merck | Virginia | state | 2016 | $450,000 | training reimbursement | |
Merck (2015) | Merck | Virginia | state | 2017 | $450,000 | training reimbursement | |
Bausch & Lomb Incorporated | Bausch Health | New York | local | 2016 | $446,809 | tax credit/rebate | |
United Therapeutics Corp | United Therapeutics | North Carolina | state | 2011 | $444,809 | tax credit/rebate | |
Ventana Medical Systems, Inc. | Roche | Arizona | state | 2005 | $443,248 | training reimbursement | |
Mallinckrodt Enterprises | Mallinckrodt | North Carolina | state | 2012 | $441,576 | tax credit/rebate | |
HOSPIRA, INC. | Pfizer | California | state | 2006 | $439,595 | training reimbursement | |
Immunex Corporation | Amgen | Pennsylvania | state | 2011 | $437,312 | tax credit/rebate | |
SmithKline Beecham Corporation DBA GlaxoSmithKline | GlaxoSmithKline | Pennsylvania | state | 2010 | $435,635 | tax credit/rebate | |
Regeneron | Regeneron Pharmaceuticals | New York | local | 2015 | $435,182 | tax credit/rebate | |
GLAXOSMITHKLINE & Stiefel Laboratories Inc. | GlaxoSmithKline | New York | local | 2014 | $432,501 | tax credit/rebate | |
Novo Nordisk Pharmaceuticals Industries, Inc. | Novo Holdings A/S | North Carolina | state | 2009 | $429,500 | tax credit/rebate | |
Pfizer Inc., and Subsidiaries | Pfizer | Maryland | state | 2015 | $427,891 | tax credit/rebate | |
Auxilium Pharmacueticals, Inc. | Endo International | Pennsylvania | state | 2014 | $426,723 | tax credit/rebate | |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2013 | $426,654 | tax credit/rebate; property tax abatement | |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2007 | $425,295 | tax credit/rebate | |
Idexx Laboratories, Inc. | IDEXX Laboratories | Maine | state | 2019 | $420,445 | tax credit/rebate | |
Novo Nordisk | Novo Holdings A/S | New Jersey | state | 2007 | $420,000 | tax credit/rebate | |
Janssen Biotech, Inc. | Johnson & Johnson | Pennsylvania | state | 2015 | $417,304 | tax credit/rebate | |
Regeneron Pharmaceuticals Inc. | Regeneron Pharmaceuticals | New York | state | 2007 | $416,897 | enterprise zone | |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2015 | $416,585 | tax credit/rebate | |
Epizyme, Inc. | Epizyme | Massachusetts | state | 2013 | $416,500 | tax credit/rebate | |
Sanofi Aventis US, Inc. | Sanofi | Pennsylvania | state | 2009 | $416,252 | tax credit/rebate | |
Eli Lilly and Company | Eli Lilly | North Carolina | state | 2015 | $416,189 | tax credit/rebate | |
United Therapeutics Corporation | United Therapeutics | North Carolina | state | 2015 | $415,729 | tax credit/rebate | |
Hospira, Inc. | Pfizer | North Carolina | state | 2016 | $415,010 | tax credit/rebate | |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2016 | $414,936 | tax credit/rebate | |
Regeneron 81 Columbia Project | Regeneron Pharmaceuticals | New York | local | 2016 | $414,840 | tax credit/rebate | |
AMYLIN OHIO LLC | AstraZeneca | Ohio | state | 2009 | $414,661 | grant | |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2010 | $414,326 | tax credit/rebate; property tax abatement | |
NewLink Genetics Corporation | Lumos Pharma | Iowa | state | 2004 | $414,200 | tax credit/rebate | |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2017 | $412,873 | tax credit/rebate | |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2011 | $410,028 | tax credit/rebate; property tax abatement | |
Regeneron Pharmaceuticals, Inc | Regeneron Pharmaceuticals | New York | Local | 2018 | $409,921 | tax credit/rebate | |
Regeneron 1 CSC Way Project | Regeneron Pharmaceuticals | New York | local | 2016 | $409,528 | tax credit/rebate | |
Abbott Laboratories | Abbott Laboratories | Illinois | state | 2007 | $409,371 | tax credit/rebate | |
Dr. Reddys Laboratories Louisiana LLC | Dr. Reddy's Laboratories | Louisiana | state | 2012 | $409,319 | property tax abatement | |
Dr. Reddys Laboratories Louisiana LLC | Dr. Reddy's Laboratories | Louisiana | state | 2009 | $409,053 | tax credit/rebate | |
Bristol-Myers Squibb Co., Inc. | Bristol-Myers Squibb | New York | Local | 2018 | $406,056 | tax credit/rebate | |
Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | Pennsylvania | state | $405,000 | tax credit/rebate | ||
United Therapeutics Corp. | United Therapeutics | North Carolina | state | 2015 | $404,026 | tax credit/rebate | |
Hospira, Inc. and Subsidiaries | Pfizer | Illinois | state | 2007 | $404,000 | tax credit/rebate |